Latest Neurimmune News & Updates

See the latest news and media coverage for Neurimmune. We track all announcements, press releases, and industry mentions in real time, all in one place.

Neurimmune

Biopharmaceutical company developing antibody therapeutics

neurimmune.com

Headquarters: Zurich Schlieren, Switzerland
Founded year: 2006
Company type: Private company
Number of employees: 60–200

Last updated Today

Latest news about Neurimmune

In short: Neurimmune expanded its pipeline through a major AstraZeneca deal, secured $150 million in growth funding, and reported positive ALS drug data.

Company announcements

5 December 2025 Neurimmune

AL-S Pharma reports positive Phase 2 AP-101 results for ALS

Study met safety endpoints with prolonged survival, delayed ventilatory support, and functional stabilization. Plans advance for confirmatory Phase 3 study.

4 December 2025 Neurimmune

Neurimmune expands collaboration with AstraZeneca for NI009

Exclusive global license agreement targets lambda light chain fibrils in AL amyloidosis. Neurimmune receives upfront payment, up to $780 million milestones, and royalties.

14 October 2025 Neurimmune

Neurimmune doses first patient in Phase 2 cliramitug study

The single-arm, multicenter NI006-102 study evaluates pharmacodynamics and safety of re-treatment in ATTR-CM patients. It assesses changes in cardiac amyloid load, structure, and function.

25 September 2025 Neurimmune

AL-S Pharma appoints Prof. Dr. Angela Genge as CMO

Renowned ALS neurologist from McGill University will lead AP-101 late-stage development. She served as global principal investigator since 2016.

Media coverage

February 11 Pharmaphorum

AstraZeneca goes bigger in amyloidosis with Neurimmune deal

AstraZeneca has clearly made the rare disease transthyretin amyloidosis (ATTR) a key component of its rare disease pipeline, licensing a second drug candidate in the...

3 December 2025 PR Newswire

Neurimmune expands collaboration with AstraZeneca to develop and commercialize fibril depleter NI009 for AL amyloidosis

/PRNewswire/ -- Neurimmune today announced that it has expanded on its transthyretin amyloid cardiomyopathy (ATTR-CM) collaboration with Alexion, AstraZeneca...

20 October 2025 startupticker.ch

Neurimmune raises $150 Million to finance its growth strategy

Neurimmune focusing on the development of immunotherapeutics for the treatment and prevention of human disorders with high unmet medical needs, announced today that it has...

4 September 2025 swissbiotech.org

Neurimmune's created AL-S Pharma announces positive results for the treatment of amyotrophic lateral sclerosis

AL-S Pharma today announced positive topline results from the Phase 2 clinical study evaluating AP-101, a potential first-in-class, disease-modifying treatment for amyotrophic lateral sclerosis (ALS...

Never miss news about Neurimmune

Track Neurimmune and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Neurimmune competitors & trending companies

Browse news for competitors to Neurimmune and other trending companies.